Abstract:
Mucositis is a pathological condition characterised by inflammation and ulceration of the mucous membranes lining the alimentary canal, particularly in the mouth (oral mucositis) and the gastrointestinal tract. It is a common side effect of cancer treatments, including chemotherapy and radiotherapy, and it is sometimes responsible for treatment interruptions. Preventing mucositis throughout the alimentary tract is therefore crucial. However, current interventions mainly target either oral or gastrointestinal side effects. This review aimed to investigate the use of systemically administered anti-inflammatory agents to prevent mucositis in cancer patients undergoing cancer treatment. PubMed, Ovid, Scopus, Web of Science, WHO ICTRP and ClinicalTrials.gov were screened to identify eligible randomised controlled trials (RCTs). The published literature on anti-inflammatory agents provides mixed evidence regarding the degree of efficacy in preventing/reducing the severity of mucositis in most anticancer treatments; however, sample size continued to be a significant limitation, alongside others discussed. Our review yielded a list of several anti-inflammatory agents that exhibit potential mucositis-preventive effects in cancer patients undergoing cancer treatment, which can be used to inform clinical practice.
摘要:
粘膜炎是一种病理状况,其特征是消化道粘膜的炎症和溃疡,特别是在口腔(口腔粘膜炎)和胃肠道。这是癌症治疗的常见副作用,包括化疗和放疗,它有时会导致治疗中断。因此,预防整个消化道的粘膜炎至关重要。然而,目前的干预措施主要针对口服或胃肠道副作用。这篇综述旨在研究全身给药抗炎药在癌症治疗中预防粘膜炎的应用。PubMed,奥维德,Scopus,WebofScience,对WHOICTRP和ClinicalTrials.gov进行了筛选,以确定合格的随机对照试验(RCT)。关于抗炎药的已发表文献提供了关于在大多数抗癌治疗中预防/减轻粘膜炎严重程度的功效程度的混合证据;然而,样本量仍然是一个很大的限制,和其他人一起讨论。我们的综述列出了在接受癌症治疗的癌症患者中表现出潜在的粘膜炎预防作用的几种抗炎药。可用于指导临床实践。